data + articles · 12 listed
newest 2025spec sheet12 rows
Sermorelin is a synthetic analogue comprising the first 29 amino acids of growth hormone-releasing hormone (GHRH), the shortest fragment that retains full biological activity at the pituitary GHRH receptor. Rather than supplying growth hormone directly, it stimulates the somatotrophs to secrete the body's own hormone, preserving the natural pulsatile rhythm and leaving intact the negative feedback that guards against overexposure. Once approved for the diagnosis and treatment of growth hormone deficiency, it is now used chiefly in compounding and research settings, where interest centers on recovery, body composition, and sleep. The broader GHRH-receptor family it belongs to is under active study for effects well beyond the pituitary, including agonist protection in heart failure and antagonist activity against prostatic hyperplasia, fibrosis, and tumor growth.
- Prompts your own growth hormone pulses
- Keeps the natural rhythm and feedback intact
- Raises IGF-1 downstream
- Trusted enough to serve as a GH test
- May deepen sleep quality
- Studied for recovery and body composition
- Mild flushing
- Occasional headache
- Occasional dizziness or nausea
Overview
Sermorelin is a 29-amino-acid peptide corresponding to the biologically active N-terminal fragment of human growth hormone-releasing hormone, GHRH(1-29), and it is recognized as the shortest synthetic peptide that retains the full growth-hormone-releasing activity of the parent hormone [1][2]. Native GHRH is a 44-residue hypothalamic peptide, and truncation to the first 29 residues preserves potency while simplifying manufacture [2].
Clinically, sermorelin was originally developed and approved as a diagnostic and therapeutic agent. Given intravenously, it serves as a relatively specific provocative test of pituitary growth hormone reserve, producing fewer false positives than some older tests, and given subcutaneously it was used to treat children with idiopathic growth hormone deficiency, where it increased height velocity and induced catch-up growth over months of therapy [1]. Reviews of the GHRH system place sermorelin among the foundational analogues used to probe the hypothalamic-pituitary axis and to treat short stature [2][3].
The originally marketed product was later discontinued, and today sermorelin is encountered chiefly through compounding pharmacies and research settings, where it is used off-label for goals such as recovery, body composition, and sleep in the context of age-related decline in growth hormone [1]. It is administered by subcutaneous injection and, as a growth-hormone secretagogue, it is prohibited in competitive sport; anti-doping laboratories have developed methods to detect sermorelin and related GHRH analogues [4]. Its enduring appeal is the concept of restoring growth hormone output through the body's own regulatory hormone, preserving the natural rhythm and safety checks of the axis rather than overriding them [1][2].
- Sermorelin is just the first 29 amino acids of GHRH, the shortest fragment that still fully activates the pituitary GHRH receptor.
- Because it boosts the body's own growth hormone, sermorelin is prohibited in competitive sport, and anti-doping chemists have mapped its metabolism to detect misuse.
Mechanism
Sermorelin acts on the GHRH receptor, a G-protein-coupled receptor on the somatotroph cells of the anterior pituitary gland. By binding this receptor it reproduces the action of endogenous GHRH, stimulating the synthesis and pulsatile release of growth hormone into the circulation [1][2]. Because it drives the pituitary rather than replacing growth hormone, downstream growth hormone in turn raises -like growth factor 1, the mediator of many of growth hormone's anabolic and metabolic effects, while the normal negative feedback from growth hormone, insulin-like growth factor 1, and somatostatin remains intact [2].
This preservation of physiological control is the mechanistic advantage that defines sermorelin. Continuous or excessive stimulation is self-limiting because somatostatin tone and receptor responsiveness modulate the output, which reduces the risk of the sustained, non-pulsatile exposure seen with exogenous growth hormone [2]. In children with idiopathic growth hormone deficiency, once-daily subcutaneous sermorelin produced significant, sustained increases in height velocity, with catch-up growth most evident in slower-growing children who had delayed bone and height age [1]. As a diagnostic stimulus, an intravenous dose reliably and relatively specifically elevates serum growth hormone, forming the basis of provocative testing [1].
The same receptor pharmacology underlies its contemporary uses and its regulatory position. Restoring more youthful pulsatile growth hormone secretion is the rationale behind its use for recovery, lean mass, and sleep, since slow-wave sleep is closely tied to nocturnal growth hormone pulses [1]. Quantitatively, the clearest defensible endpoints are the documented rises in height velocity during long-term pediatric treatment and the rapid, specific growth hormone responses used diagnostically [1]. Because it augments endogenous growth hormone, sermorelin is banned in sport, and analytical chemists have characterized its metabolism to enable detection of misuse [4]. The most common effects reported clinically are transient facial flushing and injection-site reactions, consistent with a well-tolerated secretagogue [1].
receptor fingerprint
Pituitary GHRH receptorAgonist prompting GH synthesis and release
axisIndirect rise via increased GH
Sleep / GH pulse timingReinforces the nighttime GH pulse
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Sermorelin is a growth-hormone-releasing hormone analogue that stimulates the pituitary to release growth hormone, with injection-site reactions such as redness, pain, and swelling the most common effect. By raising growth hormone and IGF-1 it can cause fluid retention, joint or muscle pain, headache, and reduced insulin sensitivity. Long-term safety in healthy adults using it for anti-aging or performance is not established, and theoretical concerns about growth hormone and IGF-1 promoting tumor growth warrant caution.
History
Sermorelin is the synthetic 1-29 amino acid fragment of growth-hormone-releasing hormone, the portion identified as the shortest sequence that retains full activity at the pituitary GHRH receptor after GHRH itself was isolated and characterized in the early 1980s. Its clinical potential was demonstrated early; in 1987, Ross and colleagues reported in The Lancet that subcutaneous GHRH (1-29) raised height velocity in growth-hormone-deficient children, establishing it as an alternative to injected growth hormone.
The molecule was subsequently approved by the U.S. FDA under the brand name Geref for the diagnosis and treatment of growth hormone deficiency, and it was later used as a provocative test of pituitary function. After the branded product was withdrawn from the market for commercial rather than safety reasons, sermorelin migrated to compounding and research settings, where interest centers on recovery, body composition and sleep.
Reputation
Sermorelin is well regarded for a mechanistic elegance that distinguishes it from directly injected growth hormone; rather than supplying the hormone, it prompts the pituitary to secrete the body's own, preserving the natural pulsatile rhythm and the negative feedback that guards against overexposure. This physiological, self-limiting quality is the main reason it remains popular for recovery, lean mass and sleep, and it carries a long clinical track record from its era as an approved medicine, where the most common complaints were merely transient flushing and injection-site reactions.
It is worth being clear that much of its modern reputation rests on that older pediatric and diagnostic evidence rather than large trials in healthy adults, and because it augments endogenous growth hormone it is banned in sport. On balance it is one of the better-characterized growth-hormone secretagogues available.
Subjective profileweighing the evidence above
The most conservative way to raise growth hormone, since it works through the pituitary and leaves the body's own feedback intact rather than overriding it, and it is well tolerated. Long-term use in healthy adults is unstudied, and the theoretical IGF-1 and tumor-growth caution deserves respect.
Where to buy
Suppliers
Vendors carrying Sermorelin, with live product details and codes. Links are affiliate links that support the wiki at no cost to you.
RUPharma🌐
Sermorelin
Exceed Enhancement
Sermorelin
Kimera Chems
Sermorelin
Limitless Biochem🌐
Sermorelin
Peptira
Sermorelin
Research
- 1986first citedGrowth hormone releasing hormone.
- 2025most recentGrowth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung C…
- 1.Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
- 2.Growth hormone releasing hormone.
- 3.A glimpse at growth hormone-releasing hormone cosmos.
- 4.Advances in the detection of growth hormone releasing hormone synthetic analogs.
- 5.Treatment of growth-hormone deficiency with growth-hormone-releasing hormone.
- 6.PEGylation of growth hormone-releasing hormone (GRF) analogues.
- 7.Growth hormone-releasing hormone agonists ameliorate chronic kidney disease-induced heart failure with preserved ejection fraction.
- 8.Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
- 9.Growth Hormone-Releasing Hormone Receptor Antagonist Modulates Lung Inflammation and Fibrosis due to Bleomycin.
- 10.Growth hormone-releasing hormone antagonist MIA-602 inhibits inflammation induced by SARS-CoV-2 spike protein and bacterial lipopolysaccharide synergism in macrophages and human peripheral blood mononuclear cells.
- 11.Growth Hormone-Releasing Hormone Antagonists Increase Radiosensitivity in Non-Small Cell Lung Cancer Cells.
- 12.Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2.
12 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
How is Sermorelin different from injecting GH?
It tells your own pituitary to release GH, so the release stays pulsatile and under normal feedback control, rather than flooding the body with outside hormone.
Was it ever an approved drug?
Yes; it was FDA-approved for GH-deficient children and as a diagnostic test, but the maker later withdrew it commercially.
Why pair it with a ghrelin-receptor peptide?
GHRH and ghrelin pathways act through different receptors, and in research they combine for a bigger GH pulse than either alone.
Adverse effects
- Mild flushing
- Occasional headache
- Occasional dizziness or nausea
Notes and cautions
- Mild injection site redness or itching